凯普生物(300639) - 2022 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2022 reached ¥1,416,056,427.12, representing a 104.33% increase year-over-year[4] - Net profit attributable to shareholders was ¥509,856,393.15, a 99.24% increase compared to the same period last year[4] - The company's revenue for the first nine months of 2022 reached ¥2,654,707,613.21, an increase of 80.74% compared to ¥1,468,809,357.59 in the same period of 2021[11] - The company achieved a revenue of 4,258.58 million yuan, representing a year-on-year growth of 113.82%[16] - The net profit attributable to shareholders reached 1,488.17 million yuan, with a year-on-year increase of 130.04%[16] - The net profit after deducting non-recurring gains and losses was 1,479.87 million yuan, up 135.06% year-on-year[16] - Total operating revenue for the current period reached ¥4,258,583,892.51, a significant increase from ¥1,991,641,765.76 in the previous period, representing a growth of approximately 113.5%[30] - Net profit for the current period was ¥1,610,962,126.40, compared to ¥683,488,650.53 in the previous period, reflecting a growth of approximately 135.9%[32] - The company reported a total profit of ¥1,938,988,783.07, up from ¥809,490,780.85, which is an increase of about 139.5%[32] Assets and Liabilities - The total assets as of September 30, 2022, amounted to ¥6,399,773,306.01, reflecting a 51.25% increase from the end of the previous year[4] - The company's total liabilities increased to RMB 1.31 billion from RMB 756 million, reflecting a growth of approximately 73%[29] - The company's equity attributable to shareholders increased to RMB 4.68 billion from RMB 3.19 billion, marking a growth of approximately 47%[29] Cash Flow - Cash flow from operating activities for the year-to-date reached ¥707,106,319.70, a 173.24% increase compared to the previous year[4] - Cash received from operating activities increased by 243.05% to ¥48,203,898.07, driven by a rise in government subsidies[11] - Cash inflow from operating activities totaled ¥2,712,767,442.45, compared to ¥1,483,641,261.22 in the previous period, indicating an increase of about 83.0%[34] - The net cash flow from investment activities was -349,243,836.93 CNY, compared to -204,577,712.64 CNY in the previous period, indicating a decline of approximately 70.5%[35] - The net cash flow from financing activities was -174,901,148.35 CNY, contrasting with a positive net flow of 113,316,648.82 CNY in the previous period[35] Research and Development - Research and development expenses rose by 99.14% to ¥159,563,544.61, indicating a significant investment in innovation[9] - The company invested 168.42 million yuan in R&D, marking a year-on-year increase of 91.32%[18] - The company has made substantial investments in research and development, focusing on women's and children's health, as part of its "Nucleic Acid 99 Strategy"[24] - The company has collaborated with various research institutions and universities to enhance its R&D capabilities and product offerings[17] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 46,125, with no preferred shareholders[13] - The largest shareholder, Hong Kong Science and Technology Venture Capital Co., Ltd., holds 29.30% of the shares, totaling 128,798,878 shares[14] - The company approved a share repurchase plan with a total fund of no less than RMB 50 million and no more than RMB 100 million, with a maximum repurchase price of RMB 25.00 per share[23] Operational Highlights - The accounts receivable increased by 145.26% to ¥2,720,974,224.75, driven by the increased demand for nucleic acid testing services[8] - The company reported a significant increase in asset disposal gains, which rose by 292.20% to ¥8,140,339.64, attributed to higher gains from fixed asset disposals[10] - The total tax expenses for the first nine months of 2022 were ¥328,026,656.67, reflecting a 160.33% increase from ¥126,002,130.32, mainly due to the increase in total profit[10] - The company has established 36 third-party medical laboratories across key provinces and cities in China, with 32 currently operational[16] - The company obtained a total of 77 medical device registration/filing certificates, including 24 Class III and 7 Class II medical device registrations[18] - The company successfully acquired land use rights for the construction of the Cap Medical Science Park for 90.79 million yuan[22] Financial Challenges - Financial expenses surged by 873.46% to ¥42,934,466.20, primarily due to significant exchange rate fluctuations[9] - Credit impairment losses increased by 276.98% to ¥121,447,605.25, primarily due to the growth in revenue and increased provisions for bad debts[10] - The cash paid to employees rose by 93.65% to ¥434,544,190.14, reflecting increased salaries and bonuses[11]